Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY)

Tipranks - Tipranks - Sat Apr 18, 6:32AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY) with bullish sentiments.

Claim 30% Off TipRanks

GE Healthcare Technologies Inc (GEHC)

Piper Sandler analyst Jason Bednar maintained a Buy rating on GE Healthcare Technologies Inc today and set a price target of $88.00. The company’s shares closed last Thursday at $73.20.

According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.4% and a 38.9% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Solventum Corporation, and Alpha Tau Medical Ltd. ;'>

Currently, the analyst consensus on GE Healthcare Technologies Inc is a Moderate Buy with an average price target of $89.50, a 21.8% upside from current levels. In a report issued on April 3, TipRanks – PerPlexity also upgraded the stock to Buy with a $79.00 price target.

See the top stocks recommended by analysts >>

Immunome (IMNM)

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Immunome, with a price target of $33.00. The company’s shares closed last Thursday at $23.26, close to its 52-week high of $25.75.

According to TipRanks.com, Amin is a 5-star analyst with an average return of 11.3% and a 48.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, OKYO Pharma Limited Sponsored ADR, and BridgeBio Oncology Therapeutics. ;'>

Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $35.36, representing a 51.6% upside. In a report issued on April 6, LifeSci Capital also maintained a Buy rating on the stock with a $40.00 price target.

Eli Lilly & Co (LLY)

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Eli Lilly & Co, with a price target of $1300.00. The company’s shares closed last Thursday at $903.99.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.6% and a 47.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Teva Pharmaceutical. ;'>

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1247.71, which is a 36.9% upside from current levels. In a report issued on April 5, TipRanks – xAI also upgraded the stock to Buy with a $1038.00 price target.

Read More on GEHC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).